Steven Horwitz, MD
Enriched profileNonna's Garden Foundation Chair; Associate Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center
Steven Horwitz is Nonna's Garden Foundation Chair; Associate Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 547 publications with 20,352 citations (h-index 71); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 1 Sept 2026
Steven Horwitz, MD, is Nonna's Garden Foundation Chair at Memorial Sloan Kettering Cancer Center. The public record shows 547 publications with 20,352 citations (h-index 71), centered on Lymphoma Diagnosis and Treatment, T-cell and Retrovirus Studies, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 13 companies, 1 NIH-funded awards (2011–2015).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lymphoma Diagnosis and Treatment
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 13 companies
Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 30 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 201.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 1 Sept 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Sponsor: Memorial Sloan Kettering Cancer Center
- MB-105 in Patients With CD5 Positive T-cell Lymphoma
Sponsor: March Biosciences Inc
- A Registry for People With T-cell Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 1 Sept 2026
13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20254 payments
- SOBI, INCProgram year20258 payments
- KYOWA KIRIN, INC.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Hormonal (systemic)
67.3%l-Thyroxine67.3%Levothyroxine Sodium100%Part D<11 patientsCancer & immunology
32.7%Retinoid32.7%Bexarotene100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 1 Sept 2026
1 NIH research award on record, funded 2011–2015 per NIH RePORTER. The latest:
Congress activity
Updated 1 Sept 2026
136 congress contributions (2006–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Anti-CD94 monoclonal antibody DR-01 induced response in a refractory primary CNS T-cell lymphoma
ASH Annual Meeting
ASH2025Co-author - CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 1 Sept 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.
Journal of clinical oncology
Review2026 - Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.
Journal of clinical oncology
Clinical Trial2026 - Extranodal natural killer/T-cell lymphoma: From fatal to curable.
CA: a cancer journal for clinicians
Review2026 - Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial.
Blood advances
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03
- 04
- 05Non-Hodgkin's LymphomasArticle457 citations2011
Network
Updated 1 Sept 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 1 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/steven-horwitz-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Steven-M-Horwitz-2143749746
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/OncLive/videos/steven-horwitz-md-of-memorial-sloan-kettering-cancer-center-presents-the-final-r/624821806803986
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →facebook.com ↗ - LinkedIn
linkedin.com/posts/onclive_steven-horwitz-md-ofmemorial-sloan-kettering-activity-7296279544456486912-UuoI
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Other
soundcloud.com/oncologydataadvisor/steven-horwitz
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →soundcloud.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 1 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗
- Internal Medicine residency
University of Rochester / Strong Memorial Hospital
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Fellowship in Medical Oncology
Stanford University Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Board Certified
Internal Medicine and Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clfoundation.org ↗
- Lymphoma Guidelines Panel member/Chair
National Comprehensive Cancer Network (NCCN)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →clfoundation.org ↗ - Editorial board member
Clinical Lymphoma and Myeloma
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →clfoundation.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- Blood Cancer United (formerly Leukemia & Lymphoma Society) award recipient
"Translational Discovery in Peripheral T-Cell Lymphomas"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bloodcancerunited.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗
Media & interviews
press, podcasts and appearances- Podcast: "Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma"
The Lancet Oncology in Conversation With
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →soundcloud.com ↗
- Podcast: "Steven Horwitz, MD, Discusses Critical Trials in PTCL"
Blood Cancers Today
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bloodcancerstoday.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center